Tumor infiltrating lymphocytes (TIL) therapy in metastatic melanoma

Autor: van den Berg, Joost H, Heemskerk, Bianca, van Rooij, Nienke, Gomez-Eerland, Raquel, Michels, Samira, van Zon, Maaike, de Boer, Renate, Bakker, Noor A M, Jorritsma-Smit, Annelies, van Buuren, Marit M, Kvistborg, Pia, Spits, Hergen, Schotte, Remko, Mallo, Henk, Karger, Matthias, van der Hage, Joris A, Wouters, Michel W J M, Pronk, Loes M, Geukes Foppen, Marnix H, Blank, Christian U, Beijnen, Jos H, Nuijen, Bastiaan, Schumacher, Ton N, Haanen, John B A G, Afd Pharmacoepi & Clinical Pharmacology, Pharmacoepidemiology and Clinical Pharmacology

Publikováno v: Journal for immunotherapy of cancer, 8(2):e000848. BioMed Central Ltd.
Journal for ImmunoTherapy of Cancer
Journal for ImmunoTherapy of Cancer, Vol 8, Iss 2 (2020)
Journal for ImmunoTherapy of Cancer, 8(2). BioMed Central
Journal for Immunotherapy of Cancer
Journal for ImmunoTherapy of Cancer, 8(2). BMJ PUBLISHING GROUP

Treatment of metastatic melanoma with autologous tumor infiltrating lymphocytes (TILs) is currently applied in several centers. Robust and remarkably consistent overall response rates, of around 50% of treated patients, have been observed across hosp

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4cf62e6d6bc568457d18aa31e0f9752b
https://hdl.handle.net/1887/3182036

Glutaminyl cyclase is an enzymatic modifier of the CD47- SIRPα axis and a target for cancer immunotherapy

Autor: Logtenberg, Meike E. W., Jansen, J. H. Marco, Raaben, Matthijs, Toebes, Mireille, Franke, Katka, Brandsma, Arianne M., Matlung, Hanke L., Fauster, Astrid, Gomez-Eerland, Raquel, Bakker, Noor A. M., van der Schot, Simone, Marijt, Koen A., Verdoes, Martijn, Haanen, John B. A. G., van den Berg, Joost H., Neefjes, Jacques, van den Berg, Timo K., Brummelkamp, Thijn R., Leusen, Jeanette H. W., Scheeren, Ferenc A., Schumacher, Ton N.

Publikováno v: Nature Medicine; April 2019, Vol. 25 Issue: 4 p612-619, 8p

PD-L1 blockade in combination with carboplatin as immune induction in metastatic lobular breast cancer: the GELATO trial.

Autor: Voorwerk L; Division of Tumor Biology and Immunology, The Netherlands Cancer Institute, Amsterdam, the Netherlands., Isaeva OI; Division of Tumor Biology and Immunology, The Netherlands Cancer Institute, Amsterdam, the Netherlands., Horlings HM; Department of Pathology, The Netherlands Cancer Institute, Amsterdam, the Netherlands., Balduzzi S; Department of Biometrics, The Netherlands Cancer Institute, Amsterdam, the Netherlands., Chelushkin M; Division of Tumor Biology and Immunology, The Netherlands Cancer Institute, Amsterdam, the Netherlands.; Division of Molecular Carcinogenesis, The Netherlands Cancer Institute, Amsterdam, the Netherlands., Bakker NAM; Division of Tumor Biology and Immunology, The Netherlands Cancer Institute, Amsterdam, the Netherlands.; Oncode Institute, Utrecht, the Netherlands., Champanhet E; Division of Tumor Biology and Immunology, The Netherlands Cancer Institute, Amsterdam, the Netherlands., Garner H; Division of Tumor Biology and Immunology, The Netherlands Cancer Institute, Amsterdam, the Netherlands.; Oncode Institute, Utrecht, the Netherlands., Sikorska K; Department of Biometrics, The Netherlands Cancer Institute, Amsterdam, the Netherlands., Loo CE; Department of Radiology, The Netherlands Cancer Institute, Amsterdam, the Netherlands., Kemper I; Department of Medical Oncology, The Netherlands Cancer Institute, Amsterdam, the Netherlands., Mandjes IAM; Department of Biometrics, The Netherlands Cancer Institute, Amsterdam, the Netherlands., de Maaker M; Division of Molecular Pathology, The Netherlands Cancer Institute, Amsterdam, the Netherlands., van Geel JJL; Department of Medical Oncology, University Medical Center Groningen, Groningen, the Netherlands., Boers J; Department of Medical Oncology, University Medical Center Groningen, Groningen, the Netherlands., de Boer M; Department of Medical Oncology, GROW, Maastricht University Medical Center, Maastricht, the Netherlands., Salgado R; Department of Pathology, GZA-ZNA hospitals, Antwerp, Belgium.; Division of Research, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia., van Dongen MGJ; Department of Medical Oncology, The Netherlands Cancer Institute, Amsterdam, the Netherlands., Sonke GS; Department of Medical Oncology, The Netherlands Cancer Institute, Amsterdam, the Netherlands., de Visser KE; Division of Tumor Biology and Immunology, The Netherlands Cancer Institute, Amsterdam, the Netherlands.; Oncode Institute, Utrecht, the Netherlands.; Department of Immunology, Leiden University Medical Center, Leiden, the Netherlands., Schumacher TN; Oncode Institute, Utrecht, the Netherlands.; Division of Molecular Oncology and Immunology, The Netherlands Cancer Institute, Amsterdam, the Netherlands.; Department of Hematology, Leiden University Medical Center, Leiden, the Netherlands., Blank CU; Department of Medical Oncology, The Netherlands Cancer Institute, Amsterdam, the Netherlands.; Division of Molecular Oncology and Immunology, The Netherlands Cancer Institute, Amsterdam, the Netherlands., Wessels LFA; Division of Molecular Carcinogenesis, The Netherlands Cancer Institute, Amsterdam, the Netherlands.; Oncode Institute, Utrecht, the Netherlands., Jager A; Department of Medical Oncology, Erasmus Medical Center, Rotterdam, the Netherlands., Tjan-Heijnen VCG; Department of Medical Oncology, GROW, Maastricht University Medical Center, Maastricht, the Netherlands., Schröder CP; Department of Medical Oncology, The Netherlands Cancer Institute, Amsterdam, the Netherlands.; Department of Medical Oncology, University Medical Center Groningen, Groningen, the Netherlands., Linn SC; Department of Medical Oncology, The Netherlands Cancer Institute, Amsterdam, the Netherlands.; Division of Molecular Pathology, The Netherlands Cancer Institute, Amsterdam, the Netherlands.; Department of Pathology, University Medical Center Utrecht, Utrecht, the Netherlands., Kok M; Division of Tumor Biology and Immunology, The Netherlands Cancer Institute, Amsterdam, the Netherlands. m.kok@nki.nl.; Department of Medical Oncology, The Netherlands Cancer Institute, Amsterdam, the Netherlands. m.kok@nki.nl.

Publikováno v: Nature cancer [Nat Cancer] 2023 Apr; Vol. 4 (4), pp. 535-549. Date of Electronic Publication: 2023 Apr 10.

Small-scale GMP production of plasmid DNA using a simplified and fully disposable production method.

Autor: Bakker NAM; Divisions of Immunology, Pharmacy & Clinical Pharmacology, The Netherlands Cancer Institute - Antoni van Leeuwenhoek, Plesmanslaan 121, 1066 CX, Amsterdam, the Netherlands; Amsterdam Biotherapeutics Unit, Louwesweg 6, 1066 EC, Amsterdam, the Netherlands., de Boer R; Divisions of Immunology, Pharmacy & Clinical Pharmacology, The Netherlands Cancer Institute - Antoni van Leeuwenhoek, Plesmanslaan 121, 1066 CX, Amsterdam, the Netherlands; Amsterdam Biotherapeutics Unit, Louwesweg 6, 1066 EC, Amsterdam, the Netherlands., Marie C; CNRS, Unité de Technologies Chimiques et Biologiques pour la Santé (UTCBS), UMR 8258, F-75006, Paris, France; INSERM, UTCBS U 1022, F-75006, Paris, France; Université Paris Descartes, Sorbonne-Paris-Cité, UTCBS, F-75006, Paris, France; Chimie ParisTech, PSL Research University, UTCBS, F-75005, Paris, France., Scherman D; CNRS, Unité de Technologies Chimiques et Biologiques pour la Santé (UTCBS), UMR 8258, F-75006, Paris, France; INSERM, UTCBS U 1022, F-75006, Paris, France; Université Paris Descartes, Sorbonne-Paris-Cité, UTCBS, F-75006, Paris, France; Chimie ParisTech, PSL Research University, UTCBS, F-75005, Paris, France., Haanen JBAG; Divisions of Immunology, Pharmacy & Clinical Pharmacology, The Netherlands Cancer Institute - Antoni van Leeuwenhoek, Plesmanslaan 121, 1066 CX, Amsterdam, the Netherlands; Divisions of Medical Oncology, The Netherlands Cancer Institute - Antoni van Leeuwenhoek, Plesmanslaan 121, 1066 CX, Amsterdam, the Netherlands., Beijnen JH; Divisions of Pharmacy & Clinical Pharmacology, The Netherlands Cancer Institute - Antoni van Leeuwenhoek, Plesmanslaan 121, 1066 CX, Amsterdam, the Netherlands., Nuijen B; Divisions of Pharmacy & Clinical Pharmacology, The Netherlands Cancer Institute - Antoni van Leeuwenhoek, Plesmanslaan 121, 1066 CX, Amsterdam, the Netherlands., van den Berg JH; Divisions of Immunology, Pharmacy & Clinical Pharmacology, The Netherlands Cancer Institute - Antoni van Leeuwenhoek, Plesmanslaan 121, 1066 CX, Amsterdam, the Netherlands; Amsterdam Biotherapeutics Unit, Louwesweg 6, 1066 EC, Amsterdam, the Netherlands. Electronic address: jh.vd.berg@nki.nl.

Publikováno v: Journal of biotechnology [J Biotechnol] 2019; Vol. 306S, pp. 100007. Date of Electronic Publication: 2019 May 11.